Pediatric Osteosarcoma and Pathogenic TP53 VariantsOctober 19th 2020
TP53 was found to be the only gene with a germline de novo pathogenic or likely pathogenic variant in pediatric patients with osteosarcoma, according to findings from the Children’s Oncology Group that were published in JCO Precision Oncology.
Nivatrotamab Granted Orphan Drug Status for Pediatric NeuroblastomaOctober 8th 2020
The FDA has granted an orphan drug designation and rare pediatric disease designation to the bispecific antibody nivatrotamab for the treatment of patients with neuroblastoma, according to an announcement from Y-mAbs Therapeutics, Inc.
FDA Grants Priority Review to Crizotinib for Pediatric ALK-Positive ALCLSeptember 24th 2020
The FDA has granted a priority review to a supplemental new drug application (sNDA) for crizotinib (Xalkori) in the treatment of pediatric patients with ALK-positive relapsed/refractory systemic anaplastic large cell lymphoma (ALCL), according to an announcement from Pfizer, Inc.
Blinatumomab: New Standard of Care for Pediatric, High-Risk ALLSeptember 6th 2020
Blinatumomab (Blincyto) monotherapy as consolidation therapy prior to allogeneic hematopoietic stem cell transplant (HSCT) resulted a significant improvement in event-free survival (EFS) and a lower risk of recurrence in children with high-risk B-cell precursor (BCP­)–acute lymphoblastic leukemia (ALL).
Global COVID-19 Observatory and Resource Center for Childhood Cancer Helps Providers During the PandemicJune 30th 2020
Following the arrival of the coronavirus disease 2019 pandemic, St. Jude Children's Research Hospital launched the first Global COVID-19 Observatory and Resource Center for Childhood Cancer.
International Pediatric Cancer Registry Can Improve OutcomesMay 31st 2020
Pediatric precision oncology in a real-world, multinational setting is feasible. For the subgroup of children with very high priority level targets, the INFORM registry provided therapeutic opportunities and new diagnostic information.
FDA Approves First-Ever Drug for Pediatric Neurofibromatosis Type 1April 11th 2020
The FDA approved selumetinib (Koselugo) to treat pediatric patients aged 2 years or older with neurofibromatosis type 1. This is the first-ever therapy approved for this rare genetic disorder, which causes tumors to grow on nerves.
FDA Approves Dasatinib for Pediatric Ph+ ALLJanuary 3rd 2019
The FDA has approved dasatinib (Sprycel) tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
Radiation Treatment May Impair Recent Memory in Pediatric Patients With Brain TumorsSeptember 24th 2018
Children with pediatric posterior fossa tumors like medulloblastoma who are treated with radiotherapy may be less likely to recall specific details of events that occurred after treatment compared with events that happened before, according to study results published in the Journal of Neuroscience.